Ebos Group posts 13% increase in interim profit on growing GLP-1 demand
Make us a preferred source
Make us a preferred source on Google
The news: Healthcare products distributor Ebos Group reported statutory net profit after tax of $125 million for the six months to December 2025, representing a 13% increase from the prior corresponding period. This was driven by solid demand across the healthcare and animal care markets.
The numbers: The group’s half-year statutory earnings before interest and tax grew 9.7% year-on-year to $303 million, while gross operating revenue saw an 8.6% increase to $868 million.
The healthcare segment delivered an 11.1% rise in revenue to $6.3 billion, while animal care saw a 48.3% revenue increase to $451 million.
Ebos declared an interim dividend of 57 NZ cents per share (48 cents), unchanged from the prior year.
The context: The company attributed the results to continued demand in the healthcare segment with growth in GLP-1 products supporting sales during the period.
Growth in the animal care division was underpinned by the acquisition and integration of New Zealand-based veterinary wholesaler SVS and Next Generation Pet Foods.
The company reaffirmed its FY26 guidance, with further improvement expected as productivity and utilisation continue to improve.
The source: ASX
